Novartis and SciNeuro collaborate on antibodies for Alzheimer’s
Novartis Pharma and SciNeuro Pharmaceuticals have agreed a worldwide licensing and collaboration agreement to advance SciNeuro’s novel amyloid beta targeted antibody programme for the treatment of Alzheimer’s disease. The programme has identified de novo antibody candidates that incorporate SciNeuro’s proprietary blood brain barrier shuttle technology… Read More